Is Q-Line Biotech the Best Stock in Its Sector? A Look at the Numbers

Q-Line Biotech CMP Rs 598 (16 Oct 2026). Market cap Rs 1,396 Cr. ROE 22.63%. P/E 25.04x versus Industry P/E 54.37x.

Is Q-Line Biotech the best stock in its sector? The stock trades on the NSE at Rs 598 as of 16 October 2026, within its 52-week range of Rs 431.00 to Rs 735.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Q-Line Biotech

Q-Line Biotech Ltd is a diagnostics company that develops and makes rapid test kits and related reagents. It is a recent listing on the NSE SME platform, so its trading history is short and it supplies diagnostic products to both domestic and overseas customers. At a market capitalisation of Rs 1,396 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Q-Line Biotech the Best Stock in Its Sector?

Q-Line Biotech makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Q-Line Biotech’s 25.04x P/E is below the 54.37x Industry P/E, Thyrocare Technologies at 44.76x and Dr Lal PathLabs at 59.51x, while its 22.63% ROE is lower than Thyrocare Technologies at 27.85%, though higher than Dr Lal PathLabs at 20.13%, and its debt to equity ratio of 0.92 is above Thyrocare Technologies at 0.09 and Dr Lal PathLabs at 0.08.

Metric	Q-Line Biotech
CMP (NSE)	Rs 598.30
52-Week High / Low	Rs 735.00 / Rs 431.00
Market Cap	Rs 1,396 Cr
P/E (TTM) vs Industry P/E	25.04x vs 54.37x
P/B	2.86
ROE	22.63%
EPS (TTM)	Rs 23.89
Dividend Yield	0.00%
Debt to Equity	0.92

Compare Q-Line Biotech Against Other Healthcare Sector Stocks

How Q-Line Biotech Compares Against Its Healthcare Sector Peers

The table below sets Q-Line Biotech against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Q-Line Biotech	1,396	25.04	22.63%	0.92
Thyrocare Technologies	7,873	44.76	27.85%	0.09
Dr Lal PathLabs	32,511	59.51	20.13%	0.08
Peer average (2 companies)	–	52.13	23.99%	0.08

Measured against the peer averages, Q-Line Biotech’s P/E is 52 percent below the 52.13x average, and its ROE is 1.36 percentage points below the 23.99% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Q-Line Biotech Worth Watching in Healthcare

• Scale: At Rs 1,396 Cr, its market capitalisation is smaller than Thyrocare Technologies (Rs 7,873 Cr) and Dr Lal PathLabs (Rs 32,511 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Wider adoption of point of care and rapid testing, together with export demand for diagnostic kits, shapes the volume and mix of its sales.
• Key risk: As an SME platform stock with a short listing history, it can see low liquidity and wide price swings, and its debt to equity ratio is close to 1, which leaves less cushion if sales slow.

Q-Line Biotech Valuation: Is It Justified?

At a P/B ratio of 2.86, the market pays about Rs 2.86 for every rupee of book value, and the EPS (TTM) of Rs 23.89 is the earnings base behind the P/E. The stock trades about 19 percent below its 52-week high and about 39 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Q-Line Biotech and other Healthcare sector stocks.

How to Track Q-Line Biotech Before You Invest

Before deciding whether Q-Line Biotech deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Q-Line Biotech to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Q-Line Biotech gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Healthcare depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Q-Line Biotech the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Q-Line Biotech has a 22.63% ROE and trades at 25.04x P/E against a 54.37x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 23.99% peer average and its P/E is below the 52.13x peer average. Its debt to equity ratio of 0.92 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Q-Line Biotech?

Ans. Q-Line Biotech was trading at Rs 598.30 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 431.00 to Rs 735.00. That leaves the share price 19 percent short of the 52-week high and 39 percent clear of the 52-week low. Its market capitalisation is Rs 1,396 Cr and its EPS (TTM) is Rs 23.89, which is the earnings figure behind the 25.04x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Q-Line Biotech belong to?

Ans. Q-Line Biotech is classified under the Healthcare sector on Univest, and that group of listed companies is the reference point for the 54.37x Industry P/E used in this article. The 2 named peers compared here are Thyrocare Technologies and Dr Lal PathLabs, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Healthcare sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Q-Line Biotech compare to its sector peers on P/E?

Ans. Q-Line Biotech’s P/E of 25.04x is below the 52.13x average of the 2 named peers, with Thyrocare Technologies at 44.76x and Dr Lal PathLabs at 59.51x. It also sits below the 54.37x Industry P/E, which is the benchmark for the wider Healthcare sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 2.86 gives one more view of how the market values its book value.

What is Q-Line Biotech’s return on equity?

Ans. Q-Line Biotech reported a return on equity of 22.63%, which is below the 23.99% average of its named peers, with Thyrocare Technologies at 27.85% and Dr Lal PathLabs at 20.13%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.92 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Q-Line Biotech based on its sector position?

Ans. Sector position is only one input into an investment decision. Q-Line Biotech has a 22.63% ROE and a 25.04x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.